Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InflaRx ( (IFRX) ) has shared an update.
On January 8, 2026, InflaRx announced a strategic realignment that sharply prioritizes the development of its oral C5aR inhibitor izicopan in hidradenitis suppurativa and other inflammation and immunology indications, supported by plans for a Phase 2b program in HS, further proof-of-concept work in chronic spontaneous urticaria and other diseases, and a pharmacokinetic bridging study in China to accelerate broader global development. To fund this focus and extend its cash runway to mid-2027, the company is cutting its workforce by about 30%, recording an estimated one-time charge of roughly $7 million largely tied to a vilobelimab inventory write-off, substantially scaling back Gohibic (vilobelimab) commercial spending while maintaining support for the BARDA-sponsored ARDS study and emergency-use availability in the U.S., and preparing a virtual capital markets day in spring 2026 to showcase izicopan’s clinical profile and commercial potential, a shift that underscores izicopan’s centrality to InflaRx’s future value creation and may reshape expectations for the company’s cost base and growth trajectory.
The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Underperform.
InflaRx’s overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and cash flow challenges. Technical analysis indicates bearish momentum, further weighing on the stock’s outlook. Valuation concerns, with a negative P/E ratio and no dividend yield, also contribute to the low score.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system, specifically the C5a/C5aR axis. Its lead program is izicopan (INF904), an orally administered small-molecule C5aR inhibitor in Phase 1 and Phase 2a development for inflammatory diseases including hidradenitis suppurativa, while its pipeline also includes vilobelimab (Gohibic), an intravenous anti-C5a monoclonal antibody that has shown disease-modifying activity in multiple clinical studies. Founded in 2007, InflaRx operates out of Jena and Munich in Germany and Ann Arbor, Michigan in the United States, with a market focus on addressing unmet needs across a range of inflammation and immunology indications.
Average Trading Volume: 2,952,232
Technical Sentiment Signal: Sell
Current Market Cap: $78.55M
See more insights into IFRX stock on TipRanks’ Stock Analysis page.